Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

NanoSight Announce New Appointment

Published: Tuesday, June 26, 2012
Last Updated: Tuesday, June 26, 2012
Bookmark and Share
Leading UK scientist, Dr Andrew Shuttleworth, joins NanoSight board as Director of Diagnostic Sciences.

NanoSight announced the appointment of renowned UK scientist and former government advisor, Dr Andrew Shuttleworth, as Director of Diagnostic Sciences.

NanoSight welcomes Dr Andrew Shuttleworth to the board of the company in the capacity of Director of Diagnostic Sciences. Dr Shuttleworth's appointment further strengthens the scientific team. His experience will greatly add to NanoSight's position as the UK's fastest growing Biotechnology company.

Andrew Shuttleworth brings a wealth of scientific knowledge to the rapidly expanding NanoSight organization. Having been awarded degrees in in applied biological sciences and virology, he spent twenty years at Porton Down research establishments involved in both fundamental research in microbiology and immunology, and the application of that research to medical and defense issues; particularly the rapid identification of select biological agents. This led to a leading role in the development of the UK's first practical biological agent detection system, fielded during the Gulf War in 1991, and acted as the scientific liaison on chemical and biological issues with UK and US Forces throughout the Gulf region. Andrew returned to Porton Down where he directed a team of analytical chemists, microbiologists and operational analysts providing chemical and biological risk and threat assessments. He also provided real-time operational advice and support to the Ministry of Defence, the Home Office and other government departments. In 2001, Andrew took up an appointment with the UK Foreign & Commonwealth Office to provide scientific advice and expertise on a diverse range of topics of national interest.

CEO Jeremy Warren says "Our growing involvement in characterization of exosomes and microvesicles has been driven by users. Increasingly we are recognizing major potential in exosome diagnostics, so the fit with Andrew is remarkable. He has followed development of NanoSight's technology since we began and been an advisor to some of our shareholders plus he has a depth of diagnostics experience. This appointment is as obvious as it is attractive for all parties."

Andrew Shuttleworth comments: "The emerging field of exosomes and nanovesicles now looks set to give rise to a fundamental shift in the way in which disease is detected, diagnosed and monitored. Currently, it is a growing research field, which NanoSight is exploiting fully through the provision of increasingly capable research instrumentation. Eventually, multiple biomarkers will be identified for each relevant disease state and this will drive the development of new analytical capabilities. Whilst it is too early to suggest that NanoSight technology will supplant existing capabilities (e.g. ELISA, qPCR), it would be prudent to recognize that NanoSight has the potential to do so – particularly where multiple-parameter tests and quantitative results might be desirable. NanoSight also has the potential to assist in the development of other novel assay systems that might be needed to fully exploit the potential benefits of exosomes and nanovesicles."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Jagiellonian University Uses NTA to Characterize Catalytic Nanoparticles
NTA used in the Faculty of Chemistry for the characterization of catalytic materials in environmental applications.
Thursday, July 11, 2013
The Institute of Water Resources & Water Supply Implements NTA to Characterize Colloids in Water
Professor Mathias Ernst has adopted the use of NTA technique to provide new insights into water quality.
Wednesday, June 26, 2013
Caltech Uses NTA to Characterize New Therapeutic Nanoparticles
Caltech to study nanoparticle-based therapeutics for the treatment of dementia, Parkinson's and Alzheimer's diseases.
Wednesday, May 01, 2013
Method Development to Estimate the Purity of Vesicle Preparations
Nanoparticle tracking analysis is used to estimate the purity of vesicle preparations at the Cardiff University School of Medicine.
Thursday, February 28, 2013
Polymer Nanoparticles Used as Drug Carriers Characterized Using Nanoparticle Tracking Analysis
NanoSight reports on how Nanoparticle Tracking Analysis, NTA, is used to help with the characterization of polymeric nanoparticles synthesized as drug carrier systems.
Tuesday, February 12, 2013
NanoSight to Receive Queen's Award for Enterprise
Company announced it has been selected to receive the Queen's Award for Enterprise in the category for International Trade 2012.
Wednesday, May 02, 2012
The EU Definition of Nanomaterials – Getting what you wished for?
NanoSight’s Jeremy Warren, CEO, offers the latest news and views on the EU definition on nanomaterials.
Tuesday, May 01, 2012
Duke University Uses NTA to Characterize "Nanoconstructs" for Biomedical Applications
NTA to characterize metal nanoparticle construct materials for use in biosensing, imaging and cancer therapy.
Friday, April 20, 2012
“Nanomaterials” Defined by European Commission
Watchers of European legislation will recognise this as a watershed and a major move which will have consequence outside Europe.
Thursday, December 15, 2011
NanoSight wins Technology World's 2011 Business Innovation Award
The technology manufacturers are winners of this year's Technology World's 2011 Business Innovation Award in the category of Energy & Environment after receiving a record number of entries surrounding their optical detection and real time analysis of sub-micron particles.
Tuesday, December 06, 2011
NanoSight Recognized as the UK's Fastest Growing Biotech Company
Company has been ranked Fast 50 in the Deloitte 2011 UK technology ranking.
Thursday, November 17, 2011
NanoSight Latest Interactive Webinar: September 22nd Subject: Exosome Characterization by Nanoparticle Analysis
Latest webinar aimed at those with a similar interest in the detection and speciation of exosomes and micro-vesicles.
Friday, September 09, 2011
Landmark Publication Reports Potential of Exosomes as Biomarkers for Early Disease Detection
NanoSight reports the new publication in one of the most cited peer reviewed journals in nanoscience and nanotechnology, NanoMedicine.
Thursday, July 07, 2011
NanoSight announces interactive webinar on January 27th on Exosome Characterization by Nanoparticle Tracking Analysis
NanoSight, world-leading manufacturers of unique nanoparticle characterization technology, will host an interactive webinar on the subject of exosome characterization by Nanoparticle Tracking Analysis.
Thursday, January 20, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos